← ANALYST RATINGS · TIPRANKS
Generate Biomedicines, Inc. (GENB): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $26.00, the highest $30.00, the lowest $22.00. The average is +115.1% from the last price of $12.09.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $13.50 → $12.50−7.4% | Hold | +3.4% | Reiterated | 17.10.26on TipRanks 13:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $13.00 → $12.00−7.7% | Hold | −0.7% | Reiterated | 17.10.26on TipRanks 13:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $13.00 → $12.00−7.7% | Hold | −0.7% | Reiterated | 17.10.26on TipRanks 13:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $12.50 → $12.00−4.0% | Hold | −0.7% | Reiterated | 17.10.26on TipRanks 13:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $13.00 → $12.00−7.7% | Hold | −0.7% | Reiterated | 17.10.26on TipRanks 13:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $13.00 → $12.00−7.7% | Hold | −0.7% | Reiterated | 17.10.26on TipRanks 13:05 | — | |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $30.00 | Buy | +148.1% | Reiterated | 14.10.26on TipRanks 10:35 | +3.2%next day +4.0% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $26.00 | Buy | +115.1% | Reiterated | 14.10.26on TipRanks 07:25 | +3.2%next day +4.0% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $22.00 | Buy | +82.0% | Assigned | 17.08.26on TipRanks 08:55 | +0.8%next day +3.2% · 5 days +14.1% | ↗ |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | $30.00 | Buy | +148.1% | Reiterated | 24.06.26on TipRanks Jun 25 07:50 | +5.2%next day +1.0% · 5 days 0.0% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $26.00 | Buy | +115.1% | Reiterated | 09.04.26on TipRanks Apr 10 13:40 | −4.0%next day −1.0% · 5 days +6.2% | ↗ |
| Eric Schmidt FCA★★★★★★★★★★#358 · hits 51% · avg +84.1% | Cantor Fitzgerald | — | Buy | — | Initiated | 24.03.26on TipRanks 06:30 | −3.6%next day −2.2% · 5 days +4.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Generate Biomedicines, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $25.33 at a price of $15.02 (+68.7%); now: $26.00 at $12.09 (+115.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 4 | 5 | 4 | 8 |
| Buy | 4 | 2 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · General
About Generate Biomedicines, Inc.
- CEO: Michael T. Nally
- Employees: 312
- 101 South Street, Somerville, MA, 02143, US
- generatebiomedicines.com
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Data from the stock’s TipRanks forecast page, read 120 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗